Roivant Sciences Ltd. (ROIV) is facing mounting bearish pressure, with short interest reaching a 12-month peak. According to ORTEX data as of November 7, 2026, short interest now accounts for 5.7% of the company's free float. This represents a 10% increase over the past month, following a significant step-change in early October. While borrowing costs remain relatively low at 0.42% APR, the steady accumulation of short positions suggests growing skepticism among market participants. The situation is further complicated by significant insider activity, with President Eric Venker executing $21.1 million in stock sales under a 10b5-1 plan, contributing to a broader 90-day net insider selling figure of approximately $43.9 million. Investors should monitor whether this build in short interest precedes further volatility.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.